Curie Brief
Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.
News
A phase 3 trial just gave multiple myeloma treatment a major upgrade. The IberDd regimen — iberdomide plus daratumumab and dexamethasone — more than doubled the rate of MRD-negative complete response compared to the standard DVd regimen in patients with relapsed/refractory multiple myeloma. These results supported the FDA's accelerated approval of IberDd in August 2026, marking a new standard of care as early as first relapse.
A new triplet therapy is reshaping the treatment landscape for relapsed/refractory multiple myeloma. Data from the phase 3 EXCALIBER-RRMM trial, presented at the 23rd International Myeloma Society Annual Meeting, showed that iberdomide (IberDd) combined with daratumumab and dexamethasone achieved an MRD-negative complete response rate of 41.1% — more than double the 20.7% seen with the standard daratumumab, bortezomib, and dexamethasone (DVd) regimen. The benefit held up across key subgroups, including patients with lenalidomide-refractory disease and those with high-risk cytogenetics.
These results were compelling enough to earn IberDd an FDA accelerated approval in August 2026 for adults with multiple myeloma who've had at least one prior line of therapy. Investigators called it a "watershed moment," noting that MRD-negative CR as a primary endpoint could offer patients faster access to effective treatments.
By the Numbers
Why it matters: IberDd sets a new bar for early relapse myeloma treatment, particularly for patients already refractory to lenalidomide — a group with historically limited options. With PFS data still maturing, the full picture of long-term benefit is yet to come.
